Eric O’Brien

626 total citations
16 papers, 194 citations indexed

About

Eric O’Brien is a scholar working on Hematology, Molecular Biology and Immunology. According to data from OpenAlex, Eric O’Brien has authored 16 papers receiving a total of 194 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Hematology, 8 papers in Molecular Biology and 4 papers in Immunology. Recurrent topics in Eric O’Brien's work include Acute Myeloid Leukemia Research (9 papers), Histone Deacetylase Inhibitors Research (3 papers) and Protein Degradation and Inhibitors (3 papers). Eric O’Brien is often cited by papers focused on Acute Myeloid Leukemia Research (9 papers), Histone Deacetylase Inhibitors Research (3 papers) and Protein Degradation and Inhibitors (3 papers). Eric O’Brien collaborates with scholars based in United States, Japan and Australia. Eric O’Brien's co-authors include Mark Wunderlich, Benjamin Mizukawa, John P. Perentesis, James C. Mulloy, H. Leighton Grimes, Nicole Manning, Susumu Goyama, Toshio Kitamura, Xin Duan and Wei Liu and has published in prestigious journals such as Journal of Clinical Investigation, Nature Communications and The Journal of Experimental Medicine.

In The Last Decade

Eric O’Brien

15 papers receiving 193 citations

Peers

Eric O’Brien

HEMAT

ONCOL

IMMUN

Michela Carlet Germany

Giacomo Volpe United Kingdom

Subbaiah Chary Nimmagadda Germany

Sewa Rijal Australia

Anne-Katrine Frank Denmark

Sonali Narang United States

Marianne Santaguida United States

Lisa von Paleske Germany

Corinna Albers Germany

Felicia Kathrine Bratt Lauridsen Denmark

Michela Carlet Germany

Eric O’Brien

137 ×1.4

71 ×0.8

HEMAT

49 ×0.9

ONCOL

47 ×1.3

IMMUN

20 ×0.8

Citations per year, relative to Eric O’Brien Eric O’Brien (= 1×) peers Michela Carlet

Countries citing papers authored by Eric O’Brien

Since Specialization

Citations

This map shows the geographic impact of Eric O’Brien's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric O’Brien with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric O’Brien more than expected).

Fields of papers citing papers by Eric O’Brien

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric O’Brien. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric O’Brien. The network helps show where Eric O’Brien may publish in the future.

Co-authorship network of co-authors of Eric O’Brien

This figure shows the co-authorship network connecting the top 25 collaborators of Eric O’Brien. A scholar is included among the top collaborators of Eric O’Brien based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric O’Brien. Eric O’Brien is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Garrett, Matthew C., Yonghua Zhuang, Farah Barakat, et al.. (2025). CPI203, a BET inhibitor, down-regulates a consistent set of DNA synthesis genes across a wide array of glioblastoma lines. PLoS ONE. 20(5). e0306846–e0306846. 1 indexed citations

Snyder, Jennifer, et al.. (2025). Abstract 3155: High-throughput drug repositioning identifies dinaciclib as a potent osteosarcoma inhibitor. Cancer Research. 85(8_Supplement_1). 3155–3155. 1 indexed citations

O’Brien, Eric, et al.. (2024). High-Throughput Drug Repurposing Identifies SN-38 As a Potent Inhibitor of AML with Synergistic Effects in Combination with PARP and BCL-2 Inhibitors for Treating KMT2A-Rearranged Leukemias. Blood. 144(Supplement 1). 2203–2203.

Hassan, Aishlin, Kathleen Hueneman, Averil Ma, et al.. (2024). Chemotherapy resistance in acute myeloid leukemia is mediated by A20 suppression of spontaneous necroptosis. Nature Communications. 15(1). 9189–9189. 8 indexed citations

Garrett, Matthew C., Daniel Woo, Eric O’Brien, et al.. (2023). HDAC1 and HDAC6 are essential for driving growth in IDH1 mutant glioma. Scientific Reports. 13(1). 12433–12433. 12 indexed citations

Wunderlich, Mark, Nicole Manning, Eric O’Brien, et al.. (2021). PD-1 Inhibition Enhances Blinatumomab Response in a UCB/PDX Model of Relapsed Pediatric B-Cell Acute Lymphoblastic Leukemia. Frontiers in Oncology. 11. 642466–642466. 17 indexed citations

O’Brien, Maureen M., Eric O’Brien, Robin E. Norris, et al.. (2021). V2 Trial: A phase I study of venetoclax and CPX-351 for young patients with relapsed/refractory acute leukemia.. Journal of Clinical Oncology. 39(15_suppl). TPS7052–TPS7052. 3 indexed citations

Bolanos, Lyndsey, Kathleen Hueneman, Morgan M. Walker, et al.. (2020). Targeting AML-associated FLT3 mutations with a type I kinase inhibitor. Journal of Clinical Investigation. 130(4). 2017–2023. 24 indexed citations

Hayashi, Yasutaka, Susumu Goyama, Shuhei Asada, et al.. (2019). Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia. Nature Communications. 10(1). 4869–4869. 33 indexed citations

10.

Wunderlich, Mark, Nicole Manning, Anthony Sabulski, et al.. (2019). Improved chemotherapy modeling with RAG-based immune deficient mice. PLoS ONE. 14(11). e0225532–e0225532. 20 indexed citations

11.

Meyer, Sara E., David E. Muench, Andrew M. Rogers, et al.. (2018). miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential. The Journal of Experimental Medicine. 215(8). 2115–2136. 20 indexed citations

12.

O’Brien, Eric, Mitali Basu, William Seibel, et al.. (2018). Predicting Drug Response and Novel Therapeutic Candidates Using Signatures of Molecular Alterations in Hematologic Malignancies. Blood. 132(Supplement 1). 2219–2219. 1 indexed citations

13.

Mizukawa, Benjamin, Eric O’Brien, Daniel C. Moreira, et al.. (2017). The cell polarity determinant CDC42 controls division symmetry to block leukemia cell differentiation. Blood. 130(11). 1336–1346. 36 indexed citations

14.

Goyama, Susumu, Mahesh Shrestha, Wendy R. Miller, et al.. (2016). Protease-activated receptor-1 inhibits proliferation but enhances leukemia stem cell activity in acute myeloid leukemia. Oncogene. 36(18). 2589–2598. 16 indexed citations

15.

Goyama, Susumu, Mahesh Shrestha, Eric O’Brien, et al.. (2016). Protease-Activated Receptor 1 (PAR-1) Inhibits Proliferation but Enhances Leukemia Stem Cell Activity in Acute Myeloid Leukemia. Blood. 128(22). 2730–2730. 1 indexed citations

16.

Mizukawa, Benjamin, et al.. (2013). Maintenance Of Bone Marrow Residency and Self-Renewal Of Leukemic Stem Cells By Cdc42 Gtpase. Blood. 122(21). 2889–2889. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact